The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include: 

 • COSMIC313 Triplet therapy improves PFS however no OS benefit in first line ccRCC 

• KEYMAKER-U03 investigates novel immune and targeted therapy in refractory ccRCC 

 • KIM1 shows promise as a prognostic and predictive biomarker predicting immunotherapy benefit in ccRCC